Skip to main content

Table 4 HIVDR mutations by treatment status among 16 FSW with detectable HIVDR in Guinea-Bissau

From: The HIV care continuum and HIV-1 drug resistance among female sex workers: a key population in Guinea-Bissau

Drug class HIVDR Mutation (n = 16) Treatment Naive (n = 5) ART experienceda (n = 11) Total (n = 16)
NNRTI K103N/S 3 (60.0%) 4 (36.4%) 7 (43.8%)b
  A98G 0 (0.0%) 2 (18.2%) 2 (12.5%)
  E1238A 0 (0.0%). 1 (9.1%) 1 (6.3%)
  K238N 0 (0.0%) 1 (9.1%) 1 (6.35)
  K238T 0 (0.0%) 1 (9.1%) 1 (6.3%)
  P225H 0 (0.0%) 1 (9.1%) 1 (6.3%)
  V106A 0 (0.0%) 1 (9.1%) 1 (6.3%)
  V179E 0 (0.0%) 1 (9.1%) 1 (6.3%)
  Y188H 0 (0.0%) 1 (9.1%) 1 (6.3%)
  Y188L 1 (20.0%) 0 (0.0%) 1 (6.3%)
NRTI M184V 0 (0.0%) 6 (54.5%) 6 (37.5%)b
  M41L 1 (20.0%) 1 (9.1%) 2 (12.5%)
  T215Y 0 (0.0%) 2 (18.2%) 2 (12.5%)
  D67N 1 (20.0%) 0 (0.0%) 1 (6.3%)
  E44D 0 (0.0%) 1 (10.0%) 1 (6.3%)
  K219E 1 (20.0%) 0 (0.0%) 1 (6.3%)
  T215FY 0 (0.0%) 1 (9.1%) 1 (6.3%)
  T215I 1 (20.0%) 0 (0.0%) 1 (6.3%)
PI L89V 0 (0.0%) 1 (9.1%) 1 (6.3%)b
  1. Data are n (%)
  2. ART antiretroviral therapy, HIVDR HIV-1 drug resistance, NNRTI non-nucleoside reverse transcriptase inhibitors, NRTI nucleoside reverse transcriptase inhibitor, PI protease inhibitors
  3. aIncluding 10 study participants with current ART use and 1 study participant with previous ART use
  4. bThe most common HIVDR in each drug class highlighted in italics